drugset / Trial / NCT07137689

A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function

NCT07137689

Phase 1 Completed 32 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to help determine the right dose of LY3537982 in participants with kidney problems, particularly those with severe kidney problems. The study will last about 43 days for each participant.

Timeline

Start
2025-08-18
Primary completion
2026-04-10
Completion
2026-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olomorasib Small molecule Oral